DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of EUR 26.77 billion. The enterprise value is 26.47 billion.
Market Cap | 26.77B |
Enterprise Value | 26.47B |
Important Dates
The last earnings date was Thursday, July 24, 2025.
Earnings Date | Jul 24, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | 392.16M |
Shares Outstanding | n/a |
Shares Change (YoY) | -2.97% |
Shares Change (QoQ) | +0.17% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 389.43M |
Valuation Ratios
The trailing PE ratio is 55.00 and the forward PE ratio is 33.37.
PE Ratio | 55.00 |
Forward PE | 33.37 |
PS Ratio | 7.31 |
PB Ratio | 12.22 |
P/TBV Ratio | 12.77 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.32, with an EV/FCF ratio of 54.46.
EV / Earnings | 54.39 |
EV / Sales | 7.21 |
EV / EBITDA | 32.32 |
EV / EBIT | 45.12 |
EV / FCF | 54.46 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 1.00.
Current Ratio | 1.52 |
Quick Ratio | 1.30 |
Debt / Equity | 1.00 |
Debt / EBITDA | 2.69 |
Debt / FCF | 4.52 |
Interest Coverage | 36.17 |
Financial Efficiency
Return on equity (ROE) is 22.83% and return on invested capital (ROIC) is 8.44%.
Return on Equity (ROE) | 22.83% |
Return on Assets (ROA) | 6.08% |
Return on Invested Capital (ROIC) | 8.44% |
Return on Capital Employed (ROCE) | 17.10% |
Revenue Per Employee | 357,281 |
Profits Per Employee | 47,476 |
Employee Count | 10,300 |
Asset Turnover | 0.61 |
Inventory Turnover | 3.05 |
Taxes
In the past 12 months, DexCom has paid 181.03 million in taxes.
Income Tax | 181.03M |
Effective Tax Rate | 27.11% |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 76.28 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 73.22 |
Average Volume (20 Days) | 2 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 2.47 |
Income Statement
In the last 12 months, DexCom had revenue of EUR 3.66 billion and earned 486.63 million in profits. Earnings per share was 1.22.
Revenue | 3.66B |
Gross Profit | 2.15B |
Operating Income | 585.15M |
Pretax Income | 667.66M |
Net Income | 486.63M |
EBITDA | 786.19M |
EBIT | 585.15M |
Earnings Per Share (EPS) | 1.22 |
Balance Sheet
The company has 2.49 billion in cash and 2.20 billion in debt, giving a net cash position of 298.03 million.
Cash & Cash Equivalents | 2.49B |
Total Debt | 2.20B |
Net Cash | 298.03M |
Net Cash Per Share | n/a |
Equity (Book Value) | 2.19B |
Book Value Per Share | 5.59 |
Working Capital | 1.47B |
Cash Flow
In the last 12 months, operating cash flow was 841.03 million and capital expenditures -354.99 million, giving a free cash flow of 486.04 million.
Operating Cash Flow | 841.03M |
Capital Expenditures | -354.99M |
Free Cash Flow | 486.04M |
FCF Per Share | n/a |
Margins
Gross margin is 58.77%, with operating and profit margins of 15.98% and 13.29%.
Gross Margin | 58.77% |
Operating Margin | 15.98% |
Pretax Margin | 18.23% |
Profit Margin | 13.29% |
EBITDA Margin | 21.47% |
EBIT Margin | 15.98% |
FCF Margin | 13.27% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 2.97% |
Shareholder Yield | n/a |
Earnings Yield | 1.82% |
FCF Yield | 1.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
DexCom has an Altman Z-Score of 5.47 and a Piotroski F-Score of 6.
Altman Z-Score | 5.47 |
Piotroski F-Score | 6 |